(Q35020538)

5 August 2017

1 reference

title

Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy (English)

1 reference

5 August 2017

1 reference

1 reference

Gerald Batist

1

1 reference

5 August 2017

Jeremy Barton

2

1 reference

5 August 2017

Philip Chaikin

3

1 reference

5 August 2017

Christine Swenson

4

1 reference

5 August 2017

Lauri Welles

5

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

Expert Opinion on Pharmacotherapy

5 August 2017

1 reference

5 August 2017

3

1 reference

5 August 2017

12

1 reference

5 August 2017

1739-1751

1 reference

Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity

5 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1739

21 January 2018

Liposomal doxorubicin

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1739

The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1739

Interaction of some daunomycin derivatives with deoxyribonucleic acid and their biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1739

Stereochemistry of Intercalation: Interaction of Daunomycin with DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1739

NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1739

Mechanism of adriamycin cardiotoxicity: evidence for oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1739

Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1739

Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1739

Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1739

Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1739

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1739

Trastuzumab in the treatment of metastatic breast cancer : anticancer therapy versus cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1739

Cardiac dysfunction in the trastuzumab clinical trials experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1739

Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.12.1739

10.1517/14656566.3.12.1739

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference